Back to first-pass browser

First-pass extracted concept

genome editing

Candidate: concept label6 source documents8 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

GE

Extracted Explainers

What the tool is doing

Genome editing is discussed as an innovative strategy for enhancing crop resilience.

Source 4DOIPubMed

Genome editing is named as a recent enabling technology for CAR-b3b4 T-cell development. The abstract does not specify a particular editing target or protocol.

Source 5DOIPubMed

What problem it solves

It is framed as a route toward designing next-generation crops with improved yield and resilience under climate-driven stress.

Source 4DOIPubMed

Evidence Snippets

emerging techniques such as genome editing, synthetic chromosomes, and high-resolution imaging
Evidence 1Source 1DOIPubMedprovenance
Editorial: Advancing plant defense: genome editing, RNAi, and synthetic biology for sustainable pest control.
Evidence 2Source 2DOIPubMedprovenance
Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders.
Evidence 3Source 3DOIPubMedprovenance
We further discuss innovative strategies for enhancing crop resilience, including genome editing, integrative multi-omics analyses, and synthetic biology applications.
Evidence 4Source 4DOIPubMedprovenance
We highlight recent advances in cutting-edge technologies such as multi-signal integration, genome editing
Evidence 5Source 5DOIPubMedprovenance
Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification.
Evidence 6Source 6DOIPubMedprovenance

Supporting Sources

Source 6primary paper2025MEDDOIPubMed
1 evidence snippet1 linked claimClaim 1

Linked Claims

Claim 1capabilitysupports2026Source 3DOIPubMed

Genome editing allows precise changes to DNA and offers potential treatments for inherited and acquired disorders.

Quoted textsource-backed
Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders.
Claim 2practical frameworksupports2026Source 1DOIPubMed

The review provides a practical framework intended to guide experiment design that balances biological relevance, sensitivity, and interpretability for identifying direct regulators of a gene of interest.

Claim 3regulatory guidancesupports2026Source 3DOIPubMed

FDA and EMA guidance for clinical genome editing emphasizes rigorous preclinical testing, patient monitoring, ethical consent, and compliance with legal frameworks.

Quoted textsource-backed
The Food and Drug Administration (FDA) and European Medicines Agency (EMA), as regulatory agencies for key advanced therapy markets, provide detailed guidance on these aspects, emphasizing rigorous preclinical testing, patient monitoring, ethical consent, and compliance with legal frameworks.
Claim 4risksupports2026Source 3DOIPubMed

Clinical genome editing faces major technical challenges from inadvertent on-target and off-target DNA alterations and unintended modification of non-target cells.

Quoted textsource-backed
Inadvertent on- and off-target DNA alterations and unintended modification of non-target cells pose major technical challenges
Claim 5topic scopesupports2026Source 2DOIPubMed

The editorial frames advancing plant defense for sustainable pest control in terms of genome editing, RNA interference, and synthetic biology.

Claim 6application potentialsupports2025Source 4DOIPubMed

Genome editing, integrative multi-omics analyses, and synthetic biology applications are discussed as innovative strategies for enhancing crop resilience.

Quoted textsource-backed
We further discuss innovative strategies for enhancing crop resilience, including genome editing, integrative multi-omics analyses, and synthetic biology applications.
Claim 7keyword themesupports2025Source 6DOIPubMed

Keyword co-occurrence highlighted AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification as major themes.

Quoted textsource-backed
Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification.
Claim 8technology landscapesupports2025Source 5DOIPubMed

Recent CAR-b3b4 T-cell advances highlighted by the review include multi-signal integration, genome editing, and off-the-shelf platform development.